Analysis of neurodevelopmental disorder in neonatal jaundice

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K17363
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 52050:Embryonic medicine and pediatrics-related
• Research Institution: Shimane University
• Principal Investigator: Miura Shoko 島根大学, 医学部, 特別協力研究員 (20749832)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: ビリルビン脳症 / セロトニン伝達異常 / セロトニン2A受容体アンタゴニスト / ADHD

Outline of Final Research Achievements

Our results suggest that higher serotonergic transmission voided the downregulation of 5-HT2AR mRNA expression and left the 5-HT2AR protein abundance unchanged in the frontal cortex of the Gunn rat, from which then developed the hyperactive phenotype of the rat. Although our experimental observations were limited to the frontal cortices and striata of 9-10-week-old Gunn and Wistar rats, it would be of value to be able to postulate that a therapeutic strategy for the BIND disorders would include restoration of the brain regions affected by serotonergic dysfunction to normal operation to prevent before, or to normalize after onset of the BIND manifestations.

Normalizing Hyperactivity of the Gunn Rat With Bilirubin-induced Neurological Disorders Via Ketanserin. (Pediatric Research)(https://doi.org/10.1038/s41390-021)

Free Research Field

器質性精神疾患

Academic Significance and Societal Importance of the Research Achievements

今後、BIND 由来の精神疾患(特にADHD)の治療薬開発において、5HT2A 受容体の遮断が重要な創薬ターゲットになるのではないかと予想される。